Shenzhen PrecELL Theranostic

Shenzhen PrecELL Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies, particularly CAR-T and CAR-NK treatments. The company utilizes a proprietary nanobody-based platform to enhance the specificity and efficacy of its therapeutic candidates against both liquid and solid tumors. Its lead program, PRG-1801, is a BCMA-targeted CAR-T therapy that has demonstrated promising results in clinical trials for multiple myeloma and is being co-developed with Celltrion. Beyond oncology, PrecELL is expanding its pipeline into autoimmune indications such as systemic lupus erythematosus. The company maintains integrated capabilities spanning R&D, clinical development, and GMP manufacturing in Shenzhen, China.